← Leaderboards
Arun Srivastava
University Of Florida
$10,395,461
Attributed
$15,545,335
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,545,335 · 14
By mechanism
R01$12,307,077 · 7
R21$1,216,945 · 3
T32$907,425 · 1
P01$819,794 · 2
R41$294,094 · 1
Top collaborators
- Roland W. Herzog10 shared
- Sergei Zolotukhin9 shared
- Guang-Ping Gao7 shared
- George V Aslanidi3 shared
- Dongsheng Duan2 shared
- Chen Ling1 shared
Most similar at University Of Florida
Same institution · by research overlap
- Piyush K Jain$3,149,579
- Robert McKenna$4,675,159
- Sihong Song$1,714,919
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyVectorRecombinant Adeno-Associated Virus (Raav)DependovirusLiverCapsidGenomeBaseHepatocyteTransduction EfficiencyVirusHematopoietic Stem CellsSerotypingTransfection /Expression VectorAdeno-Associated Viral VectorIn VivoNext GenerationImmune ResponseMediatingDosePhosphorylationAdeno Associated Virus GroupTyrosineLead
Grant awards (47)
Capsid- and genome-modified AAV3 vectors for hemophilia gene therapy.$704,635
R01 · FY2025 · HL · contact PI
Development of optimized AAVrh74 vectors for gene therapy of muscular dystrophies$163,754
R21 · FY2024 · AR · contact PI
Development of optimized AAVrh74 vectors for gene therapy of muscular dystrophies$213,389
R21 · FY2023 · AR · contact PI
Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectors$293,563
R01 · FY2021 · GM · contact PI
Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectors$293,563
R01 · FY2020 · GM · contact PI
Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectors$293,563
R01 · FY2019 · GM · contact PI
Next Generation of Recombinant AAV Serotype For Gene Therapy$770,648
R01 · FY2018 · HL · contact PI
AAV2 and hepatocellular carcinoma$184,688
R21 · FY2018 · AI · contact PI
Next Generation of Recombinant AAV Serotype For Gene Therapy$788,573
R01 · FY2017 · HL
AAV2 and hepatocellular carcinoma$223,096
R21 · FY2017 · AI · contact PI
Next Generation of Recombinant AAV Serotype For Gene Therapy$622,223
R01 · FY2016 · HL
Development of Optimized AAV Serotype Vectors for Human Gene Therapy$294,094
R41 · FY2016 · AI · contact PI
Next Generation of Recombinant AAV Serotype For Gene Therapy$142,500
R01 · FY2016 · HL
Next Generation of Recombinant AAV Serotype For Gene Therapy$630,906
R01 · FY2015 · HL
Next Generation of Recombinant AAV Serotype Vectors for Gene Therapy$593,093
R01 · FY2013 · HL · contact PI
Safety and efficacy of optimized AAV3 vectors in murine and NHP livers$283,018
R21 · FY2013 · EB · contact PI
Next Generation of Recombinant AAV Serotype Vectors for Gene Therapy$613,662
R01 · FY2012 · HL · contact PI
Safety and efficacy of optimized AAV3 vectors in murine and NHP livers$149,000
R21 · FY2012 · EB · contact PI
Next Generation of Recombinant AAV Serotype Vectors for Gene Therapy$597,388
R01 · FY2011 · HL · contact PI
Next Generation of Recombinant AAV Serotype Vectors for Gene Therapy$633,276
R01 · FY2010 · HL · contact PI
Mechanism of Hepatocyte Transduction by AAV Vectors$168,317
P01 · FY2009 · DK · contact PI
Human Parvovirus B19 Vectors: Mechanism of Transduction$344,900
R01 · FY2008 · HL · contact PI
Mechanism of Hepatocyte Transduction by AAV Vectors$158,034
P01 · FY2008 · DK · contact PI
Human Parvovirus B19 Vectors: Mechanism of Transduction$344,900
R01 · FY2007 · HL · contact PI
Mechanism of Hepatocyte Transduction by AAV Vectors$65,322
P01 · FY2007 · DK · contact PI
Human Parvovirus B19 Vectors: Mechanism of Transduction$355,202
R01 · FY2006 · HL · contact PI
Mechanism of Hepatocyte Transduction by AAV Vectors$217,146
P01 · FY2006 · DK · contact PI
Human Parvovirus B19 Vectors: Mechanism of Transduction$363,750
R01 · FY2005 · HL
Mechanism of Hepatocyte Transduction by AAV Vectors$210,975
P01 · FY2005 · DK
Parvovirus Vectors for Human Gene Therapy$363,750
R01 · FY2004 · EB
Human Parvovirus B19 Vectors: Mechanism of Transduction$363,750
R01 · FY2004 · HL
Hematepoietic Stem Cell Transduction by AAV2 Vectors$363,750
R01 · FY2004 · HL
Hematepoietic Stem Cell Transduction by AAV2 Vectors$182,287
R01 · FY2004 · HL
Hematepoietic Stem Cell Transduction by AAV2 Vectors$372,500
R01 · FY2003 · HL
Parvovirus Vectors for Human Gene Therapy$366,496
R01 · FY2003 · EB
BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASES$257,513
T32 · FY2003 · HL
Hematepoietic Stem Cell Transduction by AAV2 Vectors$372,500
R01 · FY2002 · HL
Parvovirus Vectors for Human Gene Therapy$370,505
R01 · FY2002 · HL
BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASES$226,126
T32 · FY2002 · HL
AAV MEDIATED TRANSDUCTION OF PRIMARY HEMATOPOIETIC CELLS$0
P01 · FY2002 · HL
Hematepoietic Stem Cell Transduction by AAV2 Vectors$370,580
R01 · FY2001 · HL
Parvovirus Vectors for Human Gene Therapy$370,505
R01 · FY2001 · HL
BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASES$231,576
T32 · FY2001 · HL
AAV MEDIATED TRANSDUCTION OF PRIMARY HEMATOPOIETIC CELLS$0
P01 · FY2001 · HL
PARVOVIRUS VECTORS FOR HUMAN GENE THERAPY$424,109
R01 · FY2000 · HL
BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASES$192,210
T32 · FY2000 · HL
AAV MEDIATED TRANSDUCTION OF PRIMARY HEMATOPOIETIC CELLS$0
P01 · FY2000 · HL